Investigating a biomarker for racial disparities in triple-negative breast cancer
HSET as a racial disparity biomarker for TNBC patients
This study is looking at how having African ancestry might influence the treatment and outcomes for African American patients with triple-negative breast cancer, and it aims to create more personalized treatment plans by examining a specific marker in their tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10875378 on NIH RePORTER |
What this research studies
This research focuses on understanding how African ancestry affects outcomes in patients with triple-negative breast cancer (TNBC). It aims to develop personalized treatment strategies for African American TNBC patients by analyzing the role of a specific biomarker, nuclear HSET, which may indicate worse prognoses for these patients. The study will involve examining tumor samples and clinical outcomes to better tailor therapies to this population. By addressing the underrepresentation of African American patients in clinical trials, the research seeks to improve treatment options and outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American patients diagnosed with triple-negative breast cancer.
Not a fit: Patients with non-triple-negative breast cancer or those who do not identify as African American may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for African American patients with triple-negative breast cancer.
How similar studies have performed: While there is ongoing research into racial disparities in cancer treatment, this specific approach focusing on the HSET biomarker in TNBC is relatively novel.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Aneja, Ritu — University of Alabama at Birmingham
- Study coordinator: Aneja, Ritu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.